Background: Photodynamic therapy (PDT) can be used for the management of peri-implantitis. This study aimed to explore the efficacy and safety of PDT for peri-implantitis in Chinese Han patients. Methods: This was a single-centre, open-label, randomized controlled trial of participants with peri-implantitis treated at the Beijing Chao-Yang Hospital, randomized 1:1 to PDT or no PDT. PDT was performed using toluidine blue (10 mg/ mL; 3 min) and a 635-nm laser (750 mW; 10 s/implant side; minimum of 60 mW/cm 2 ). The primary outcome was the decline in periodontal probing depth (PD) at 6 months. The secondary outcomes were peri-implant plaque index (PLI), sulcular bleeding index (SBI), and clinical attachment loss (CAL). Results: PD after treatment was smaller in the PDT group (n = 66) than in controls (n = 65) (all P < 0.001 vs. baseline). At 1 month, compared with controls, the PD in the PDT group was larger, while at 3-and 6-month, the PDs were smaller (all P < 0.001). CAL, PLI and SBI in the PDT group was better (P < 0.05 vs. controls). Conclusion: PDT combined with mechanical debridement significantly improves PD, PLI and SBI in participants with peri-implantitis. Importantly, PDT achieved a better CAL than mechanical debridement and cleaning.Abbreviations: AE = adverse event; CAL = clinical attachment loss; DB = distobuccal; PD = pocket depth; PDT = Photodynamic therapy; PLI = peri-implant plaque index; SBI = sulcular bleeding index.

The mandibular condylar osteochondromas may show different growth positions encircling the condyle and exhibit varying shapes on panoramic radiograph. These features will help us to increase cognition of the lesion and make an exact diagnosis.

M. Winkler, J. Pratschke, U. Schulz, S. Zheng, M. Zhang, W. Li, M. Lu, D. Sgarabotto, G. Sganga, P. Kaskel, S. Chandwani, L. Ma, J. Petrovic, M. Shivaprakash. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study. Transpl Infect Dis 2010: 12: 230–237. All rights reservedObjectiveThis study was designed to determine clinical outcomes with caspofungin in patients with proven or probable invasive fungal infection (IFI) after a solid organ transplant (SOT) procedure.MethodsIn this retrospective observational study, data were collected for a single episode of IFI in patients with an SOT between January 2004 and June 2007. Response was determined by the investigator as favorable (complete or partial) or unfavorable (stable disease or failure) at the end of caspofungin therapy (EOCT). The primary effectiveness population was the proportion of patients who received ≥5 doses of caspofungin (modified all-patients-treated population). Safety was assessed for patients who received ≥1 dose of caspofungin.ResultsA total 81 of patients from 13 sites in China, Germany, Italy, and the United Kingdom were enrolled, including 49 (60%) liver, 22 (27%) heart, 5 (6%) lung, 2 (2%) kidney, 2 (2%) liver and kidney, and 1 (1%) pancreas and kidney recipients. Candidiasis was diagnosed in 64/81 patients (79%) and aspergillosis in 22/81 patients (27%). Most patients received caspofungin monotherapy (75%). Caspofungin was given as first-line therapy to 59 (73%) patients. The overall favorable response at EOCT was 87% (58/67; 95% confidence interval [CI]: 76%, 94%), with favorable responses in 88% (43/49; 95% CI: 75%, 95%) of patients receiving caspofungin monotherapy and 83% (15/18; 95% CI: 59%, 96%) of patients receiving combination therapy with caspofungin (modified all-patients-treated population). Response by type of SOT was as follows: liver 87% (39/45), heart 93% (14/15), kidney 100% (5/5), and lung 50% (2/4). An overall survival rate (all-patients-treated) of 69% (56/81; 95% CI: 59%, 79%) was observed at 7 days post EOCT. No serious drug-related adverse events were reported.ConclusionIn this study, caspofungin was effective and well tolerated in the treatment of IFIs involving SOT recipients.

No abstract